| Artificial intelligence in pharmaceutical technology and drug delivery design LK Vora, AD Gholap, K Jetha, RRS Thakur, HK Solanki, VP Chavda Pharmaceutics 15 (7), 1916, 2023 | 462 | 2023 |
| Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management VP Chavda, LK Vora, AK Pandya, VB Patravale Drug discovery today 26 (11), 2619-2636, 2021 | 206 | 2021 |
| Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review VP Chavda, J Ajabiya, D Teli, J Bojarska, V Apostolopoulos Molecules 27 (13), 4315, 2022 | 176 | 2022 |
| Nanoparticle-based delivery systems for vaccines R Bezbaruah, VP Chavda, L Nongrang, S Alom, K Deka, T Kalita, F Ali, ... Vaccines 10 (11), 1946, 2022 | 145 | 2022 |
| SARS‐CoV‐2 variants and vulnerability at the global level VP Chavda, AB Patel, DD Vaghasiya Journal of medical virology 94 (7), 2986-3005, 2022 | 144 | 2022 |
| Applications of targeted nano drugs and delivery systems VP Chavda Nanosci Nanotechnol Drug Deli2019 18, 69-92, 2019 | 139 | 2019 |
| DNA vaccines for SARS-CoV-2: toward third-generation vaccination era VP Chavda, R Pandya, V Apostolopoulos Expert Review of Vaccines 20 (12), 1549-1560, 2021 | 112 | 2021 |
| Nanobased nano drug delivery: a comprehensive review VP Chavda Applications of targeted nano drugs and delivery systems, 69-92, 2019 | 105 | 2019 |
| Nano-drug delivery systems entrapping natural bioactive compounds for cancer: recent progress and future challenges VP Chavda, AB Patel, KJ Mistry, SF Suthar, ZX Wu, ZS Chen, K Hou Frontiers in oncology 12, 867655, 2022 | 97 | 2022 |
| Nucleic acid vaccines for COVID-19: a paradigm shift in the vaccine development arena VP Chavda, MK Hossain, J Beladiya, V Apostolopoulos Biologics 1 (3), 337-356, 2021 | 97 | 2021 |
| A global picture: therapeutic perspectives for COVID-19 VP Chavda, C Kapadia, S Soni, R Prajapati, SC Chauhan, MM Yallapu, ... Immunotherapy 14 (5), 351-371, 2022 | 85 | 2022 |
| Therapeutics for COVID-19 and post COVID-19 complications: An update D Basu, VP Chavda, AA Mehta Current Research in Pharmacology and Drug Discovery 3, 100086, 2022 | 84 | 2022 |
| The Delta and Omicron variants of SARS-CoV-2: what we know so far VP Chavda, R Bezbaruah, K Deka, L Nongrang, T Kalita Vaccines 10 (11), 1926, 2022 | 80 | 2022 |
| Exosome nanovesicles: a potential carrier for therapeutic delivery VP Chavda, A Pandya, L Kumar, N Raval, LK Vora, S Pulakkat, ... Nano Today 49, 101771, 2023 | 78 | 2023 |
| Phytochemical-loaded liposomes for anticancer therapy: An updated review VP Chavda, D Vihol, B Mehta, D Shah, M Patel, LK Vora, M Pereira-Silva, ... Nanomedicine 17 (8), 547-568, 2022 | 74 | 2022 |
| mRNA-based vaccines and therapeutics for COVID-19 and future pandemics VP Chavda, S Soni, LK Vora, S Soni, A Khadela, J Ajabiya Vaccines 10 (12), 2150, 2022 | 72 | 2022 |
| Herbal remedies, nutraceuticals, and dietary supplements for COVID-19 management: An update VP Chavda, AB Patel, D Vihol, DD Vaghasiya, KMSB Ahmed, KU Trivedi, ... Clinical Complementary Medicine and Pharmacology 2 (1), 100021, 2022 | 71 | 2022 |
| COVAX-19Ⓡ Vaccine: Completely blocks virus transmission to non-immune individuals VP Chavda, LK Vora, DR Vihol Clinical Complementary Medicine and Pharmacology 1 (1), 100004, 2021 | 69 | 2021 |
| Recent review of COVID-19 management: Diagnosis, treatment and vaccination VP Chavda, S Vuppu, T Mishra, S Kamaraj, AB Patel, N Sharma, ZS Chen Pharmacological Reports 74 (6), 1120-1148, 2022 | 68 | 2022 |
| Adenoviral vector-based vaccine platform for COVID-19: Current status VP Chavda, R Bezbaruah, D Valu, B Patel, A Kumar, S Prasad, BB Kakoti, ... Vaccines 11 (2), 432, 2023 | 65 | 2023 |
Vasso ApostolopoulosDistinguished Professor, Professor of Immunology, RMIT University, Australia.Verified email at rmit.edu.au
